Show simple item record

dc.contributor.authorUstun, Celalettin
dc.contributor.authorCerny, Jan
dc.date2022-08-11T08:09:53.000
dc.date.accessioned2022-08-23T16:47:49Z
dc.date.available2022-08-23T16:47:49Z
dc.date.issued2019-08-01
dc.date.submitted2019-09-09
dc.identifier.citation<p>Bone Marrow Transplant. 2019 Aug;54(8):1254-1265. doi: 10.1038/s41409-018-0401-4. Epub 2018 Dec 13. <a href="https://doi.org/10.1038/s41409-018-0401-4">Link to article on publisher's site</a></p>
dc.identifier.issn0268-3369 (Linking)
dc.identifier.doi10.1038/s41409-018-0401-4
dc.identifier.pmid30546070
dc.identifier.urihttp://hdl.handle.net/20.500.14038/41153
dc.description<p>Full author list omitted for brevity. For the full list of authors, see article.</p>
dc.description.abstractWe analyzed CIBMTR data to evaluate the incidence of non-relapse mortality (NRM) and association with overall survival (OS) for bacterial blood stream infections (BSIs) occurring within 100 days of alloHCT in 2 different phases: pre-/peri-engraftment (BSI very early phase, BSI-VEP) and BSI post-engraftment (BSI occurring between 2 weeks after engraftment and day 100, late early phase, BSI-LEP). Of the 7128 alloHCT patients, 2656 (37%) had > /=1 BSI by day 100. BSI-VEP, BSI-LEP, and BSI-Both constituted 56% (n = 1492), 31% (n = 824), and 13% (n = 340) of total BSI, respectively. Starting in 2009, we observed a gradual decline in BSI incidence through 2012 (61-48%). Patients with BSI-VEP were more likely to receive a myeloablative conditioning (MAC) regimen with total body irradiation (TBI). NRM was significantly higher in patients with any BSI (RR 1.82 95% CI 1.63-2.04 for BSI-VEP, RR 2.46, 95% CI 2.05-2.96 for BSI-LEP, and RR 2.29, 95% CI 1.87-2.81 for BSI-Both) compared with those without BSI. OS was significantly lower in patients with any BSI compared with patients without BSI (RR 1.36, 95% CI 1.26-1.47 for BSI-VEP; RR 1.83, 95% CI 1.58-2.12 for BSI-LEP: RR 1.66, 95% CI 1.43-1.94 for BSI-Both). BSIs within day 100 after alloHCT are common and remain a risk factor for mortality.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=30546070&dopt=Abstract">Link to Article in PubMed</a></p>
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6565512/
dc.subjectBacterial Infections and Mycoses
dc.subjectFluids and Secretions
dc.subjectHematology
dc.subjectHemic and Lymphatic Diseases
dc.subjectTherapeutics
dc.titleBacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantation
dc.typeJournal Article
dc.source.journaltitleBone marrow transplantation
dc.source.volume54
dc.source.issue8
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/3942
dc.identifier.contextkey15291878
html.description.abstract<p>We analyzed CIBMTR data to evaluate the incidence of non-relapse mortality (NRM) and association with overall survival (OS) for bacterial blood stream infections (BSIs) occurring within 100 days of alloHCT in 2 different phases: pre-/peri-engraftment (BSI very early phase, BSI-VEP) and BSI post-engraftment (BSI occurring between 2 weeks after engraftment and day 100, late early phase, BSI-LEP). Of the 7128 alloHCT patients, 2656 (37%) had > /=1 BSI by day 100. BSI-VEP, BSI-LEP, and BSI-Both constituted 56% (n = 1492), 31% (n = 824), and 13% (n = 340) of total BSI, respectively. Starting in 2009, we observed a gradual decline in BSI incidence through 2012 (61-48%). Patients with BSI-VEP were more likely to receive a myeloablative conditioning (MAC) regimen with total body irradiation (TBI). NRM was significantly higher in patients with any BSI (RR 1.82 95% CI 1.63-2.04 for BSI-VEP, RR 2.46, 95% CI 2.05-2.96 for BSI-LEP, and RR 2.29, 95% CI 1.87-2.81 for BSI-Both) compared with those without BSI. OS was significantly lower in patients with any BSI compared with patients without BSI (RR 1.36, 95% CI 1.26-1.47 for BSI-VEP; RR 1.83, 95% CI 1.58-2.12 for BSI-LEP: RR 1.66, 95% CI 1.43-1.94 for BSI-Both). BSIs within day 100 after alloHCT are common and remain a risk factor for mortality.</p>
dc.identifier.submissionpathoapubs/3942
dc.contributor.departmentDivision of Hematology Oncology, Department of Medicine
dc.source.pages1254-1265


This item appears in the following Collection(s)

Show simple item record